Table 2.

Prognostic value of enriched immune signature expression for LUAD patients.

Immune Signatures	Overall	Female	Male
IFN-G	-	-	-
Lymphocytes infiltration	Extended	Extended	-
Macrophage-Monocytes	-	Extended-	-
TGF-β	Poorer	-	Poorer
Wound healing	Poorer	Poorer	Poorer

Note for Table 2: For Overall, Female and Male cohorts respectively, the median expression value for each gene signature was calculated and compared to each individual patient gene signature mean expression, to classify patients into either the ‘High’ or ‘Low’ expression cohorts, respectively. The p-value from the Cox model using the Wald test of differences in overall survival time between ‘High’ and ‘Low’ expression cohorts was calculated. Considering the relative survival between the ‘High’ and ‘Low’ cohorts, respectively, if the p-value < 0.05, the gene signature was categorized as having either an “Extended” (blue) or “Poorer” (red) prognostic impact on survival. Otherwise the gene signature was labelled ‘-’, as having no significant prognostic impact on survival.